
ENLV Stock Forecast & Price Target
ENLV Analyst Ratings
Bulls say
Enlivex is a relatively small biotech company, but its RAIN platform has the potential to disrupt the prediction markets segment. The recent $212M private placement for shares is a strategic move to build a robust digital asset treasury center around accumulating RAIN tokens. With promising clinical trial data for Allocetra in joint diseases and a rapidly growing trading volume for RAIN tokens, Enlivex's outlook is positive and the company shows potential for significant growth.
Bears say
Enlivex is a clinical stage macrophage reprogramming immunotherapy company with a specific focus on treating osteoarthritis. Despite having developed a novel therapy and a treasury using the RAIN protocol, Enlivex has not yet generated any product revenue. Furthermore, the success of Allocetra is uncertain and the company's financials are not strong enough to weather a potential failure, making it a risky investment.
This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENLV Analyst Forecast & Price Prediction
Start investing in ENLV
Order type
Buy in
Order amount
Est. shares
0 shares